[Rituximab combined with short-course and intensive regimen for Burkitt leukemia: efficacy and safety analysis].

Li, Y; Gong, X Y; Zhao, X L; Wei, H; Wang, Y; Lin, D; Zhou, C L; Liu, B C; Wang, H J; Li, C W; Li, Q H; Gong, B F; Liu, Y T; Wei, S N; Zhang, G J; Mi, Y C; Wang, J X; Liu, K Q

Li, Y; Gong, X Y; Zhao, X L; Wei, H; Wang, Y; Lin, D; Zhou, C L; Liu, B C; Wang, H J; Li, C W; Li, Q H; Gong, B F; Liu, Y T; Wei, S N; Zhang, G J; Mi, Y C; Wang, J X; Liu, K Q.

Affiliation

Li Y; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China.
Gong XY; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China.
Zhao XL; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China.
Wei H; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China.
Wang Y; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China.
Lin D; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China.
Zhou CL; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China.
Liu BC; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China.
Wang HJ; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China.
Li CW; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China.
Li QH; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China.
Gong BF; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China.
Liu YT; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China.
Wei SN; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China.
Zhang GJ; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China.
Mi YC; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China.
Wang JX; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China.
Liu KQ; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China.

Zhonghua Xue Ye Xue Za Zhi ; 41(6): 502-505, 2020 Jun 14.

Article de Zh | MEDLINE | ID: mdl-32654465

Sujet(s)
Mots clés

Antineoplastic combined chemotherapy protocols; Burkitt leukemia; Rituximab; Treatment outcome

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Protocoles de polychimiothérapie antinéoplasique / Lymphome de Burkitt / Transplantation de cellules souches hématopoïétiques / Leucémie-lymphome lymphoblastique à précurseurs B et T / Rituximab Limites: Adolescent / Adult / Female / Humans / Male / Middle aged Langue: Zh Journal: Zhonghua Xue Ye Xue Za Zhi Année: 2020 Type de document: Article Pays d'affiliation: Chine Pays de publication: Chine

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google